Downregulation of IncRNA MALAT1 suppresses abnormal proliferation of small intestinal epithelial stem cells through miR-129-5p expression in diabetic mice

TI-DONG SHAN, ZI-BIN TIAN and YUE-PING JIANG

Department of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, Shandong 262000, P.R. China

Received September 27, 2019; Accepted January 8, 2020

DOI: 10.3892/ijmm.2020.4492

Abstract. The problems caused by diabetes mellitus (DM) and its related complications are gaining increasing attention. In our previous study, the abnormal proliferation of small intestinal epithelial cells (IECs) were observed in diabetic mice. However, little is known regarding the potential underlying mechanism. In the present study, the abnormal proliferation of IECs in DM and the marked upregulation of metastasis associated lung adenocarcinoma transcript 1 (MALAT1) was observed. Additionally, knockdown of MALAT1 significantly reduced abnormal IESC proliferation in DM mice. Bioinformatics analysis and luciferase reporter assays revealed that microRNA (miR)-129-5p was directly targeted by MALAT1. Moreover, the results of the bioinformatics prediction and luciferase assays demonstrated that MALAT1 directly interacted with SRY-box 9 (SOX9). Furthermore, MALAT1 silencing was observed to attenuate the abnormal proliferation of IESCs through the SOX9-mediated WNT/β-catenin signaling pathway. Knockdown of MALAT1 downregulated SOX9 expression by binding to miR-129-5p, thereby inhibiting the abnormal proliferation of IESCs via the WNT/β-catenin signaling pathway.

Introduction

Diabetes mellitus (DM) is a major metabolic disorder, affecting over 350 million people worldwide in 2017 (1). The increased incidence of DM is associated with an increased incidence of complications of diabetes, making DM one of the most important current public health issues (2). Diabetic enteropathy (DE) is a common complication of DM, and the majority of previous studies have examined neuron loss, which results in dysmotility and altered secretion within the entire gastrointestinal tract; therefore, it has been proposed that DE should be considered a panenteric disorder (3). However, in patients with DM, intestinal epithelial cells (IECs) often undergo significant changes. A number of recent studies have shown that DM is an independent risk factor for the occurrence and development of colorectal cancer (4,5), supporting the hypothesis that there is an association between DM and the abnormal proliferation of intestinal epithelial stem cells (IESCs).

Long noncoding RNAs (IncRNAs) constitute a cluster of transcripts that are made of >200 nucleotides, have no protein-coding ability and are able to regulate gene expression at the transcriptional, epigenetic, and translational levels (6,7). These aberrantly expressed IncRNAs may be involved in epigenetic regulatory processes, such as chromatin modification, X chromosome silencing and genetic imprinting and in the regulation of transcription, translation, protein activity, and RNA alternative splicing (8,9). The IncRNA expression profiles of a variety of tumors are significantly different. In our previous study, the knockdown of IncRNA H19 inhibited the abnormal differentiation of small IECs in diabetic mice (10). Metastasis associated lung adenocarcinoma transcript 1 (MALAT1), a highly conserved IncRNA, is expressed at high levels in the majority of cells. Previous research suggests that MALAT1 is involved in the pathogenesis of various human diseases, especially cancer. A number of recent studies point to the involvement of MALAT1 in the proliferation of cancer cells, vascular smooth muscle cells, high glucose-induced endothelial cells and periodontal ligament stem cells (11-13). However, the role of MALAT1 in the proliferation of IESCs in DM requires further understanding. MicroRNAs (miRNAs) are a major class of short (~22 nucleotides) noncoding RNAs that function to block protein translation and/or degrade...
their messenger RNA targets. They bind to complementary sequences in the 3'-untranslated regions (UTRs), 5'UTRs, and/or coding regions of target mRNAs (11). One of the most novel functions of IncRNAs is their ability to serve as competing endogenous RNAs (ceRNAs), which compete with coding RNAs for shared miRNAs, thus regulating the functions of these genes (14,15). miRNAs direct a number of important processes that are associated with cellular growth, apoptosis, differentiation, metabolism and the immune response (16). Furthermore, miRNAs are known to have a pivotal role in DM (10,17). Numerous studies have reported the roles of miR-129-5p (18-20). miR-129-5p is involved in IncRNA Trinucleotide repeat containing adaptor 6c-antisense RNA 1-mediated processes and regulates Unc-5 netrin receptor B in thyroid cancer to influence cell proliferation, migration, and invasion (18). Although studies have investigated the functions of miR-129-5p in cancer, its role in IEScs migration, and invasion (18). The normal proliferation of IEScs is gated the functions of miR-129-5p in cancer, its role in IEScs of DM needs to be investigated. In the present study, MALAT1 functions as a miRNA sponge for regulating the proliferation of IESCs in DM.

IESCs are located in the intestinal crypt, which maintains intestinal epithelial balance by regulating its own proliferation and differentiation (18,21). The normal proliferation of IESCs is maintained by highly specialized and well-regulated signaling cascades. The Wnt pathway is a classical pathway in the IEC, and this pathway acts primarily on IESCs to promote intestinal epithelial proliferation. Additionally, deregulated Wnt signaling is involved in the pathophysiological processes of numerous diseases, including the occurrence and development of cancer (22). Recent evidence suggests that Wnt/β-catenin signaling is activated under diabetic conditions (23) and that increased proliferation of IECs in diabetic rats has been associated with the accumulation of β-catenin (23). In our previous study, the abnormal proliferation of IECs in DM mice was observed (24); however, the potential mechanisms underlying the association between Wnt/β-catenin signaling pathway activation and abnormal IESC proliferation in DM are still poorly understood.

Numerous studies on MALAT1 have examined its role in the progression and prognosis of cancer (25-27). Despite the aforementioned findings, the role of MALAT1 in IESCs of DM needs to be investigated. In the present study, MALAT1 expression was significantly elevated in the IESCs of DM mice. Furthermore, it was demonstrated that MALAT1 acts as a 'molecular sponge' for miR-129-5p to regulate the abnormal proliferation of IESCs via the Wnt signaling pathway.

Materials and methods

**Streptozocin (STZ)-induced DM mouse model.** A total of 96 8-week-old male C57BL/6J mice (weight, 20-40 g) were obtained from the Animal Laboratory Center in The Affiliated Hospital of Qingdao University (Qingdao, China). All animals were maintained in a thermostatically controlled room with a 12-h light/dark cycle. Diabetes was induced by daily intraperitoneal injection of STZ (Sigma-Aldrich; Merck KGaA; 70 mg/kg) for 5 days (10,17,28); and the mice in the control group received ip injections of the same volume of citrate buffer (0.1 mol/l) for ten consecutive days (10,17,28). Then, all mice were euthanized with an intraperitoneal injection of ketamine/xylazine (100/10 mg/kg body weight). The small intestines were carefully removed and flushed with 0.1 M PBS (pH 7.4) for the isolation of primary IESCs. All experiments with mice were approved by the Animal Care Committee of The Affiliated Hospital of Qingdao University.

**RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR).** Total RNA was extracted from tissue samples and cell lines using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Then, RT was performed with PrimeScript™ RT Master mix (Takara Biotechnology Co., Ltd.). The RT conditions were as follows: 42°C for 5 min and 95°C for 10 sec. qPCR was performed on a CFX Connect™ real-time PCR detection system (Bio-Rad Laboratories, Inc.) using SYBR® Premix Ex Taq™ (Takara Biotechnology Co., Ltd.). The thermal cycling conditions were as follows: Initial denaturation at 95°C for 5 min, followed by 40 cycles of denaturation at 95°C for 15 sec and annealing/elongation at 60°C for 30 sec. miRNA expression levels were measured using the SYBR PrimeScript™ miRNA RT-PCR kit (Takara Biotechnology Co., Ltd.). miRNA samples were normalized to U6. Each experiment was repeated six times. The primers are described in Table SI. The data were analyzed using the 2^ΔΔcq method (29).

**Bioinformatics analysis.** DIANA-LncBase Predicted v.2 (http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=LncBase/index) and TargetScan 7.2 (http://www.targetscan.org/) were used to predict the putative target genes for MALAT1 and miR-129-5p.

**Culture of cell lines.** CT26 cells, NIH 3T3 cells and 293T cells were obtained from American Type culture collection. These cell lines were all cultured under standard culture conditions as described previously (10,17). Cell lines were cultured in DMEM (Invitrogen; Thermo Fisher Scientific, Inc.) with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin. Cells were grown in a 95% air, 5% CO2 atmosphere at 37°C.

**Primary IESC isolation and culture.** Primary IESCs were isolated from the small intestines of mice and cultured in Matrigel as described previously (10,17,30,31).

**Cell transfection.** The siRNAs targeting MALAT1 were purchased from GenePharma (si#1 and si#2; Shanghai GenePharma Co., Ltd.). CT26 cells and primary IESCs were seeded in six-well plates 1 day prior to transfection. The siRNAs (15 nM), miRNA mimic (15 nM) and inhibitor (15 nM) were transfected into cells according to the Lipofectamine 3000 transfection reagent protocol (Thermo Fisher Scientific, Inc.). The miRNA mimic (agomiR-129-5p) and inhibitor (antagomiR-129-5p) were all purchased from Shanghai GenePharma Co., Ltd. The silencing efficiency was evaluated at 48 h following transfection using RT-qPCR. Each experiment was repeated six times.

**Dual-luciferase reporter plasmid transfection.** The MALAT1 and SRY-box 9 (SOX9) wild-type (WT) sequences with
potential miR-129-5p-binding sites were amplified from the genomic DNA of NIH 3T3 cells and cloned into the pmiR-RB-REPORT™ plasmid (Guangzhou RiboBio Co., Ltd.). A plasmid containing a potential miR-129-5p-binding site with a mutation was used as the negative control (Guangzhou RiboBio Co., Ltd.). Mutations were introduced with the KOD-plus mutagenesis kit (Toyobo Life Science). Measurements of firefly and Renilla luciferase activity were performed using the Dual-Luciferase Reporter Assay system (Promega Corporation). Briefly, A total of 48 h after cell transfection, for the Dual-Luciferase Reporter assay, the firefly luciferase reporter was measured first by adding Luciferase Assay Reagent II to generate a stabilized luminescent signal. After the firefly luminescence was quantified for 3 min, the reaction was quenched, and the Renilla luciferase reaction was simultaneously initiated by adding Stop & Glo® reagent to the same tube. The Stop & Glo® reagent also produced a stabilized signal from the Renilla luciferase protein, which decayed slowly over the course of the measurement. The luciferase efficiency was evaluated at 2 min following Stop & Glo® reagent using SpectraMax Multifunctional Microplate Reader (Molecular Devices). Each experiment was repeated six times.

**Downregulating the expression of MALAT1 in vivo.** A total of 120 C57BL/6j mice were randomly divided into five groups, with 24 in each group. All mice received a tail vein injection once a day for 3 days. The Con-NS group comprised control mice receiving saline (0.9%; same volume as the experimental group) injections (14,15), and the DM-NS group comprised DM mice receiving saline (0.9%; same volume as the experimental group) injections (14,15); the DM-siRNA (si#1 and si#2) mice received injections of MALAT1 siRNAs (80 mg/kg body weight (14,15), and the DM-CT mice received injections of antagoniR-129-5p and MALAT1 siRNAs (80 mg/kg body weight (14,15). In each group, six mice were euthanized with an intraperitoneal injection of ketamine/xylazine (100/10 mg/kg body weight) on day 0 (prior to injection), days 2, 4 and 6 for further study. Each experiment was repeated six times.

**Fluorescence in situ hybridization.** A DIG-labeled LNA-MALAT1 probe was synthesized by Bersinbio (Guangzhou, China.) and the probe sequences are available upon request. In brief, a 5-mm section of paraffin-embedded tissues was incubated with 50% methanol in PBST (0.1% Tween-20) for 5 min, 30% methanol for 5 min, PBST solution for 5 min and then with 4% paraformaldehyde in PBS solution for 20 min at room temperature. The tissues was washed twice with PBST for 5 min at room temperature and then followed by the treatment with proteinase K (15 µg/ml; New England Biolabs) at 37°C for 15 min. After being washed three times with PBS and dried with ethanol, the section was hybridized using 30 nM LNA-MALAT1 probe at 55°C for 1 h. After three incubations with SSC buffer at 60°C for 30 min, the samples were washed with PBST (containing 0.1% Tween-20) for 15 min with three times at room temperature. The section was then incubated with anti-DIG-AP (cat. no. 11093274910; 1:300; Roche Diagnostics) at 4°C overnight. Then, the section was stained with NBT/BCIP (Thermo Fisher Scientific, Inc.) at 30°C for 2 h, and the reaction was stopped with stop-buffer. When the section was dried with ethanol, the expression of MALAT1 was determined using diaminobenzidine solution (1:900; Boster Biological Technology) for 3 min at room temperature, and the staining intensity was observed using a fluorescence microscope (Olympus Corporation). The staining was quantified by counting the number of positive cells at a magnification of x400. Each experiment was repeated six times.

**Immunochemistry.** A 5-mm section was prepared from the paraffin-embedded intestinal section, and hematoxylin and eosin (H&E) staining was further used for histological analysis. In brief, fresh tissue was fixed with 4% paraformaldehyde for 24 h at room temperature, then dehydrated with a gradient alcohol series (75% alcohol for 4 h, 85% alcohol for 2 h, 90% alcohol for 2 h, 95% alcohol for 1 h), absolute ethanol II for 30 min, alcohol benzene for 5-10 min, xylene for 5-10 min, and wax for 3 h; the wax-soaked tissue was embedded and stored at -20°C. After the wax had solidified, it was paraffin embedded and sliced. For immunohistochemistry, sections were placed in 1% hydrogen peroxide in PBS for 10 min and then placed in citrate buffer in a pressure cooker for 45 min (Beyotime Institute of Biotechnology). Goat serum (5-10%; Beyotime Institute of Biotechnology) was applied for 30 min at room temperature, and then sections were incubated with anti-BrdU (cat. no. 560210; 1:200; BD Biosciences; Becton, Dickinson and Company,) and anti-SOX9 antibody (cat. no. 82630; 1:250; Cell Signaling Technology, Inc.) antibodies overnight at 4°C. The tissue was then incubated with EnVision+/HRP/Rb (dako; Agilent Technologies, Inc.) for 30 min at room temperature. Slides were developed using 3,3-diaminobenzidine tetrahydrochloride (DAB) and counterstained with hematoxylin. The H&E-stained sections were imaged with a light microscope BX51 (Olympus Corporation) to measure the length of villi and the level of cell proliferation. The stained sections were quantified by counting the number of positive cells at a magnification of x400 in 10 contiguous, well-oriented intestinal crypts by an examiner blinded to sample identity. Each experiment was repeated six times.

**Protein extraction and western blotting.** Total protein from tissues and cells was isolated in RIPA Buffer (Thermo Fisher Scientific, Inc.) containing a protease inhibitor cocktail (Roche Applied Science). Protein samples (40 µg/sample) were separated on 10% SDS-PAGE gels. The separated proteins were transferred onto polyvinylidene fluoride membranes and blocked with 5% skim milk at room temperature for 1 h. Blots were incubated at 4°C overnight with primary antibodies: Anti-β-catenin antibody (cat. no. 8480S; 1:1,000), anti-SOX9 antibody (cat. no. 82630; 1:1,000), anti-cyclin D1 antibody (cat. no. 555065; 1:1,000), anti-cyclin-dependent kinase 2 (CDK2) antibody (cat. no. 2546; 1:1,000), anti-cell division cycle 42 (CDC42) antibody (cat. no. 2466; 1:1,000), and anti-β-actin antibody (cat. no. 4970; 1:1,000) (all from Cell Signaling Technology, Inc.). After three washes with TBS-T, the membranes were washed and incubated for 1 h with horseradish peroxidase-conjugated secondary antibody (cat. no. 7074S; Cell Signaling Technology, Inc.) at 37°C. The blots were visualized using an enhanced chemiluminescence Ultra Western HRP Substrate kit (cat. no. WBUL50100; EMD Millipore) and autoradiography with X-ray film.
Protein quantification was analyzed by Quantity One software version 4.6.2 (Bio-Rad Laboratories, Inc.) and the intensity values were normalized to β-actin. Each experiment was repeated six times.

Statistical analysis. Results are expressed as the mean ± standard deviation and analyzed using the statistical software package (SAS 8.0 for Windows; SAS Institute, Inc.). Comparisons between groups were analyzed using a Student’s test and multiple group comparisons were analyzed using one-way ANOVA with Tukey’s post hoc test. P<0.05 was considered to indicate a statistically significant difference.

Results

Abnormal proliferation of IECs in DM mice. To further evaluate IEC proliferation in DM, immunostaining was used to measure the length of the villi. The results showed that the length of the villi was significantly increased in DM mice compared with that in control mice (P<0.05; Fig. 1A). Moreover, BrdU (intraperitoneal) injection into mice was used to label the S-phase cells of the intestinal epithelium. BrdU analysis showed that the BrdU positivity of intestinal crypts in DM mice increased significantly compared with that in the control group after 1 h of BrdU injection (P<0.05; Fig. 1B). Additionally, the number of BrdU-positive cells in DM mice increased significantly after 24 h (P<0.05; Fig. 1C). To detect a significant increase in intestinal cell proliferation, SOX9 staining was performed, which is a marker for the crypt cell population containing stem and progenitor cells. The crypts in the IECs of the DM mice contained an increased number of SOX9-positive cells compared with those of the control mice (P<0.05; Fig. 1D). Based on the observed abnormal proliferation of IECs, the levels of several important cell cycle-related proteins were determined. An increased expression of cyclin D1, CDK2, and CDC42 was observed in the IECs of the DM mice compared with the control group (P<0.05; Fig. 1E and F). These findings suggest that the abnormal proliferation of stem cells in the crypt may be responsible for the elongation of villi in DM mice.

MALAT1 is upregulated in the IESCs of DM mice. To determine whether MALAT1 is expressed in the IESCs of DM mice, its expression profile was examined. Interestingly, RT-qPCR analysis revealed that MALAT1 levels were significantly upregulated in the IESCs of DM compared with normal tissues (P<0.05; Fig. 1A). Fluorescence in situ hybridization of a DIG-labeled LNA-MALAT1 probe further showed that
MALAT1 was predominantly localized to the cytoplasm of the intestinal crypt and that expression of MALAT1 in DM mice was significantly increased (P<0.05; Fig. 2B and C). Therefore, it was hypothesized that MALAT1, whose function is still not fully understood, plays an important role in the abnormal proliferation of IECs in DM mice.

Knockdown of MALAT1 inhibits the abnormal proliferation of IESCs in DM mice. To study the functional role of MALAT1 in the IESCs of DM, knockdown of MALAT1 in primary IESCs and CT26 cells was conducted. RT-qPCR showed that siRNA-mediated knockdown of MALAT1 significantly downregulated the expression of MALAT1 in both cell lines (P<0.05; Fig. 3A). Additionally, tail vein injections of two siRNAs against MALAT1 into DM mice were performed. MALAT1 expression in the IESCs of DM-siRNAs mice was significantly downregulated at 2, 4 and 6 days compared to that in DM-NS mice (P<0.05; Fig. 3B). MALAT1 expression on the 4th day after DM-siRNA injection was similar to that in the Con-NS mice. On the 4th day after DM-siRNA injection, BrdU was injected into DM-siRNA mice. One hour after the BrdU injection, the increase in BrdU positivity in the intestinal crypts was significantly inhibited in the DM-siRNA mice (P<0.05; Fig. 3C) and close to the levels observed in the Con-NS mice (P<0.05; Fig. 3C). Additionally, SOX9 expression was measured using immunohistochemistry, and the expression of SOX9-positive cells in DM-siRNA mice was significantly decreased after siRNA administration (P<0.05; Fig. 3D). These data indicate that MALAT1 may be involved in IESC proliferation in DM mice.

miR-129-5p directly binds and downregulates MALAT1. To further investigate the potential mechanism by which MALAT1 contributes to the abnormal proliferation of IESCs, DIANA-LncBase Predicted v.2 and the TargetScan database were used to predict a MALAT1 microRNA target and selected miR-129-5p (P<0.05; Fig. 4A). To verify the prediction, wild-type (MALAT1-WT) and miR-129-5p-binding-site mutant (MALAT1-MUT) MALAT1 luciferase reporters were constructed. As shown in Fig. 4B-D, miR-129-5p expression significantly attenuated the luciferase activity of the reporter with WT MALAT, but did not attenuate that of the mutant reporter (P<0.05). To further assess the potential association between miR-129-5p and MALAT1, primary IESCs and CT26 cells were transfected with antagoniR-129-5-p or agomiR-129-5p. It was demonstrated that restoration of miR-129-5p significantly reduced MALAT1 levels, whereas antagonism of miR-129-5p increased MALAT1 expression (P<0.05; Fig. 4E and F). Taken together, these results indicate that MALAT1-mediated promotion of IESC proliferation is partly dependent on miR-129-5p sponging.

miR-129-5p regulates WNT/β-catenin signaling by targeting SOX9. The WNT/β-catenin signaling pathway is essential for maintaining the development and homeostasis of IECs. Overexpression of miR-129-5p in primary IESCs and CT26 cells was performed and it was demonstrated that β-catenin mRNA and protein expression levels decreased. Inhibition of miR-129-5p expression resulted in the significant upregulation of β-catenin expression levels (P<0.05; Fig. 5A-C). SOX9 was identified as a downstream target of miR-129-5p using the TargetScan (http://www.targetscan.org) online database. There are two putative SOX9 binding sites within miR-129-5p: Regions 599-605 and 608-614 (Fig. 5D). Activity analysis demonstrated that luciferase expression in IESCs and CT26 cells that were cotransfected with miR-129-5p and the SOX9-WT plasmid were significantly decreased compared with that of the cells cotransfected with miR-129-5p and the SOX9-MUT plasmid or transfected with the SOX9-WT plasmid alone (P<0.05; Fig. 5E). To further assess the potential association between miR-129-5p and SOX9, cells were transfected with antagoniR-129-5-p or agomiR-129-5p. As shown in Fig. 5F, forced expression of miR-129-5p significantly decreased SOX9 mRNA expression, while inhibition of miR-129-5p expression significantly increased SOX9 expression at the mRNA level (P<0.05); likewise, the protein expression of SOX9 was significantly decreased and increased, respectively (P<0.05; Fig. 5G and H). Our previous study showed that SOX9 regulates WNT/β-catenin signaling in the IESCs of diabetic mice (25). These data further showed that miR-129-5p regulates WNT/β-catenin signaling by targeting SOX9.

MALAT1 knockdown results in the downregulation of β-catenin expression through miR-129-5p in DM mice. First, primary IESCs and CT26 cells were transfected with siRNAs or cotransfected them with antagoniR-129-5-p and siRNAs; the inhibition of MALAT1 significantly suppressed SOX9 and β-catenin expression, whereas inhibition of miR-129-5p partly abolished the silencing effect of MALAT1 knockdown on
SOX9 and β-catenin (P<0.05; Fig. 6A-C). Then, to investigate the biological role of MALAT1 in the abnormal proliferation mechanism of IESCs in DM, siRNAs were subcutaneously injected into mice. The levels of SOX9 and β-catenin protein in the DM-siRNA mice were significantly reduced compared with those in the DM-NS mice (P<0.05; Fig. 6D and E) and were similar to those in the Con-NS mice. Additionally, the expression levels of SOX9 and β-catenin proteins were higher in DM-CT mice compared with in DM-siRNA mice (P<0.05; Fig. 6D and E) and similar to those in DM-NS mice. More importantly, in our previous study, β-catenin was localized to the crypts of IESCs (10). These results suggest that MALAT1 can regulate WNT/β-catenin signaling by sequestering endogenous miR-129-5p in the IESCs of DM.

Discussion

As a complication of DM, DE is often present in diabetic patients, and there is still a lack of early diagnosis and effective treatment measures to mitigate the harmful and potentially irreversible effects of DE on the small intestine. A growing body of evidence indicates that abnormal expression of lncRNAs is associated with tumorigenesis and development, and that certain lncRNAs are associated with poor cancer prognosis (32-34). In fact, previous studies have demonstrated that MALAT1 can cause the tumorigenesis and development of multiple types of tumors, as well as abnormal development of vascular smooth muscle and endothelial cells (12,13). However, the role of MALAT1 in the IESCs of DM is still poorly understood. In the present study, a pathogenic role for MALAT1 was revealed in the IESCs of DM and its possible molecular mechanisms were elucidated. The findings suggested that MALAT1 is a specific lncRNA that causes the abnormal proliferation of IESCs in DM. In the present study, MALAT1 expression was significantly increased in the IESCs of DM mice. IESCs are located in the intestinal crypt of the intestinal epithelium and are mainly responsible for the renewal of IECs. Fluorescence in situ hybridization of a DIG-labeled LNA-MALAT1 probe showed that MALAT1 appears to be predominantly localized to the crypts of IECs and to the cytoplasm of crypt cells. Taken together, the data indicate that MALAT1 appears to play an important role in regulating the cell fate of the IESC in DM. Although the classical pathway for controlling IESC proliferation has been studied, little is known about the underlying molecular mechanisms controlling IESC proliferation (10,17,24,35). In our previous studies, we found an increase in the number of goblet cells, Paneth cells, and absorptive cells and a reduction in endocrine cells in DM mice (10,17). Immunostaining was used to show that the length of the villi was significantly increased in DM
mice. Moreover, BrdU positivity was significantly higher in the intestinal crypts of DM mice than in those of normal mice after 1 and 24 h. Given that IESCs are highly dependent on IESC function, whether Sox9 affects IESCs was investigated. It was observed that the crypts in the IESCs of the DM mice contained an increased number of Sox9-positive cells compared with those of the control mice. The precise balance between IESC proliferation and the principal molecular determinant of IESC proliferation remains to be elucidated. Inspired by these results, it was hypothesized that MALAT1 may be involved in the abnormal proliferation of IESCs in DM. Using loss-of-function methods in vivo, it was revealed that MALAT1 plays a key role in the abnormal proliferation of IESCs in DM. Following siRNA injections into DM mice, the abnormal proliferation of IESCs was normalized according to the results of BrdU assays. These results indicate that inhibiting MALAT1 may be an effective method to prevent the abnormal proliferation of IESCs in DM mice. However, it remained plausible that other upregulated lncRNAs or even downregulated lncRNAs may exhibit large differences in the DM model. Additionally, the regulatory network of lncRNAs appears to be complex and may be highly dependent on the cellular context. Thus, more research is needed in the future.

Recently, emerging evidence has suggested that lncRNAs regulate miRNAs by functioning as endogenous sponges, and it has been experimentally demonstrated that miRNA targeting regulates the stability of lncRNAs (36,37). In accordance with the ceRNA hypothesis, MALAT1 also functions as a decoy.

Figure 4. miR-129-5p directly targets MALAT1. (A) miR-129-5p binds to the MALAT1 sequence. Luciferase activity was detected in (B) primary IESCs, (C) CT26 cells and (D) 293T cells. Reverse transcription-quantitative polymerase chain reaction was used to analyze the association between miR-129-5p and MALAT1 in (E) IESCs and (F) CT26 cells. n=6; *P<0.05 vs. control group; #P<0.05 vs. mutant group. IESCs, intestinal epithelial stem cells; MALAT1, metastasis associated lung adenocarcinoma transcript 1; miRNA/miR, microRNA; WT, wild type; MUT, mutant; agomiR, agonist miR; antagomiR, antagonist miR.
to reduce or eliminate the effects of ceRNAs on their native mRNA targets. With the help of bioinformatics analysis, MALAT1 was confirmed to harbor miR-129-5p binding sites. To further clarify this, the association between MALAT1 and
miR-129-5p was analyzed by performing luciferase assays. Restoration of miR-129-5p levels reduced MALAT1 levels, whereas antagonism of miR-129-5p increased MALAT1 expression. These studies indicate that miR-129-5p directly inhibits MALAT1 expression by directly targeting MALAT1.

As a class of nucleic acid-based molecules, miRNAs have therapeutic potential, depending on their characteristics, to modulate one or more gene targets within a particular signal transduction pathway, or even one or more targets across multiple independent pathways (38). Study has also confirmed the important role of miRNAs in the abnormal proliferation of cancer stem cells (39). Studies have shown that miR-129-5p plays important roles in regulating the proliferation of various human cancer types (40) and in

Figure 6. MALAT1 knockdown induces the downregulation of β-catenin levels. (A) The levels of SOX9 and β-catenin in primary IECs and CT26 after transfection with siRNAs or co-transfection with antagomiR-129-5p and siRNAs were determined by western blotting analysis. Quantification of (B) SOX9 and (C) β-catenin protein levels. n=6; *P<0.05 vs. NC; †P<0.05 vs. siRNA groups. (D) Representative image and (E) quantification of the protein levels of miR-129-5p targets in DM mice after tail vein injections of siRNAs or cotransfection with antagomiR-129-5p or siRNAs. n=6; *P<0.05 vs. DM-NS group; †P<0.05 vs. DM-siRNA group. IECs, intestinal epithelial stem cells; miRNA/miR, microRNA; siRNA/si, small interfering RNA; antagomiR, antagonist miR; SOX9, SRY-box 9; MALAT1, metastasis associated lung adenocarcinoma transcript 1; Con-NS, control mice receiving saline; DM-NS, DM mice receiving saline; DM-si, DM mice receiving siRNA; DM-CT, DM mice receiving antagomiR-129-5p and MALAT1 siRNAs.
diabetes (41). However, in the diabetic context, the mechanism of miR-129-5p actions in the proliferation of IESCs remains unclear. In the present study, bioinformatics analysis suggested that SOX9 was a target of miR-129-5p. To further confirm that SOX9 was a target of miR-129-5p, the effect of cotransfection of the miR-129-5p and SOX9-WNT plasmids was investigated by evaluating luciferase activity. The analysis showed that luciferase expression in cells cotransfected with miR-129-5p and the SOX9-WT plasmid was significantly decreased compared with that in cells cotransfected with miR-129-5p and the SOX9-MUT plasmid or transfected with the SOX9-WT plasmid alone. Thus, the luciferase reporter analysis confirmed that SOX9 is a target gene of miR-129-5p. To further confirm the association between miR-129-5p and SOX9, SOX9 expression was evaluated in primary IESCs and CT26 cells after transfection of miR-129-5p mimic or inhibitor. It was found that SOX9 expression was decreased at the mRNA and protein levels after upregulation of miR-129-5p expression. In contrast, downregulation of miR-129-5p expression increased SOX9 expression at the mRNA and protein levels. These results confirm that miR-129-5p could directly target SOX9 and suggest a potential mechanism for regulating SOX9 expression. Our previous study showed that SOX9 regulates WNT/β-catenin signaling in IESCs in the diabetic context (30).

In mammals, the WNT/β-catenin signaling pathway is essential for maintaining IESC proliferation and IEC homeostasis (42-44). The effect of MALAT1 on the Wnt/β-catenin pathway has not been fully investigated under diabetic conditions. To further elucidate the underlying molecular mechanism of abnormal IESC proliferation in DM, the expression of MALAT1 in DM was examined by transfecting siRNAs in vitro and in vivo. After transfection of siRNA in primary IECs and DM mice, the downregulation of MALAT1 inhibited the expression of SOX9 and β-catenin, in a similar manner to that of the miR-129-5p mimic. Furthermore, lowering the expression of miR-129-5p partially offset the silencing effect of MALAT1 on these genes. Therefore, the effect of MALAT1 on IESC proliferation in DM could be explained in part by its function as a molecular sponge of miR-129-5p, thereby confirming the role of MALAT1 in the regulatory mechanism of IESC proliferation. A study has demonstrated that the upregulation of MALAT1 is induced by activation of the Wnt/β-catenin pathway (45). However, there are numerous reports on MALAT1-mediated regulation of β-catenin expression (26,46). In this study, in the context of diabetes, the downregulation of MALAT1 was demonstrated to inhibit the expression of SOX9 and β-catenin. We hypothesize that in the complex signaling networks of cells, adjustments between MALAT1 and β-catenin may occur through direct or indirect means, which may depend on different conditions. Thus, there is a need for more research in the diabetic context.

The results of the present study showed that IESC proliferation depended partly on MALAT1 expression. The potential mechanisms underlying these effects involve the regulation of the WNT/β-catenin signaling pathways, MALAT1 actions as a molecular sponge for miR-129-5p and MALAT1-mediated regulation of its target gene SOX9. Furthermore, evidence for an apoptotic mechanism that serves to govern the proliferation of IESCs in DM was provided, offering a platform for the development of targeted therapeutics.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (grant no. 81800461).

Funding

No funding was received.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors’ contributions

TDS conceived the study, wrote the original draft, collected the data for the proliferation of IESCs and investigated the SOX9-mediated WNT/β-catenin signaling pathway in mice. ZBT collected the expression data of MALAT1 in mice. YPJ and ZBT provided the resources and supervised the study. TDS and YPJ reviewed and edited the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of the Affiliated Hospital of Qingdao University (Qingdao, China).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


